[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fiuWybTiQ2tgMiCtIN805iTs3fuA0nAnH40CHP1GM38o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":64,"rows":71},"CHU de Reims",[4],273,false,46,9,71283,11,221,[14,17,20,22,24,26,29,31],{"name":15,"count":16},"Bullous Pemphigoid",6,{"name":18,"count":19},"Obesity",4,{"name":21,"count":19},"Bipolar Disorder",{"name":23,"count":19},"Alzheimer Disease",{"name":25,"count":19},"Pregnancy",{"name":27,"count":28},"Cancer",3,{"name":30,"count":28},"Alcohol Use Disorder",{"name":32,"count":28},"Periodontitis",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06479018","Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid","2025-01-10","Blood sampling",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT02924818","Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases","2026-11","blood test",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05888987","Use of a New Method for the Microbiological Diagnosis of Severe Corneal Infection","2027-01-07","PCR multiplex by FilmArray",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06176248","Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis","2027-01-11","Triamcinolone Acetonide",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06442995","Evaluation of the Efficacy of the Addition of Magnesium Sulfate to Morphine on the Occurrence of Acute Urinary Retention Following Epidural Anesthesia for Cesarean Section.","2027-07","Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06475469","Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk","2028-06","Blood sampling & Chest CT without",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,98,116,139,157,180,204,222,240,262,280,301,329,347,375,393,411,438,456,481,499,524,550,577,595,621,639,666,691,717,776,812,847,883,920,944,962,986,1010,1035,1060,1085,1103,1131,1158,1176,1194,1220,1238,1264,1293,1317,1343,1368,1393,1427,1452,1477,1502,1529,1547,1573,1600],{"intervention":58,"totalTrials":73,"cells":74},1,{"EARLY_PHASE1":75,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":96},{"trials":76,"activeCount":77},[],0,{"trials":79,"activeCount":77},[],{"trials":81,"activeCount":77},[],{"trials":83,"activeCount":77},[],{"trials":85,"activeCount":73,"soonestReadout":57},[86],{"nctId":55,"briefTitle":56,"status":87,"phases":88,"primaryCompletion":57,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"RECRUITING",[69],"2027-12","2025-01-16",290,[93],"Urinary Retention",[58,95],"Injection of Isotonic saline + 2 mg morphine into the epidural space",{"trials":97,"activeCount":77},[],{"intervention":95,"totalTrials":73,"cells":99},{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":114},{"trials":101,"activeCount":77},[],{"trials":103,"activeCount":77},[],{"trials":105,"activeCount":77},[],{"trials":107,"activeCount":77},[],{"trials":109,"activeCount":73,"soonestReadout":57},[110],{"nctId":55,"briefTitle":56,"status":87,"phases":111,"primaryCompletion":57,"completion":89,"start":90,"enrollment":91,"conditions":112,"interventions":113},[69],[93],[58,95],{"trials":115,"activeCount":77},[],{"intervention":53,"totalTrials":73,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":128},{"trials":119,"activeCount":77},[],{"trials":121,"activeCount":77},[],{"trials":123,"activeCount":77},[],{"trials":125,"activeCount":77},[],{"trials":127,"activeCount":77},[],{"trials":129,"activeCount":73,"soonestReadout":52},[130],{"nctId":50,"briefTitle":51,"status":87,"phases":131,"primaryCompletion":52,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},[70],"2027-03","2024-10-11",62,[136],"Adhesive Capsulitis",[53,138],"saline solution",{"intervention":138,"totalTrials":73,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":142,"activeCount":77},[],{"trials":144,"activeCount":77},[],{"trials":146,"activeCount":77},[],{"trials":148,"activeCount":77},[],{"trials":150,"activeCount":77},[],{"trials":152,"activeCount":73,"soonestReadout":52},[153],{"nctId":50,"briefTitle":51,"status":87,"phases":154,"primaryCompletion":52,"completion":132,"start":133,"enrollment":134,"conditions":155,"interventions":156},[70],[136],[53,138],{"intervention":48,"totalTrials":73,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":160,"activeCount":77},[],{"trials":162,"activeCount":77},[],{"trials":164,"activeCount":77},[],{"trials":166,"activeCount":77},[],{"trials":168,"activeCount":77},[],{"trials":170,"activeCount":73,"soonestReadout":47},[171],{"nctId":45,"briefTitle":46,"status":87,"phases":172,"primaryCompletion":47,"completion":173,"start":174,"enrollment":8,"conditions":175,"interventions":179},[],"2027-08-07","2023-07-07",[176,177,178],"Infectious Keratitis","Microbial Keratitis","Corneal Infection",[48],{"intervention":43,"totalTrials":73,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":192},{"trials":183,"activeCount":77},[],{"trials":185,"activeCount":77},[],{"trials":187,"activeCount":77},[],{"trials":189,"activeCount":77},[],{"trials":191,"activeCount":77},[],{"trials":193,"activeCount":73,"soonestReadout":42},[194],{"nctId":40,"briefTitle":41,"status":87,"phases":195,"primaryCompletion":42,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},[70],"2036-11","2016-11-15",225,[200],"Chronic Inflammatory Pulmonary Diseases",[43,202,203],"microbiology","histology",{"intervention":202,"totalTrials":73,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":216},{"trials":207,"activeCount":77},[],{"trials":209,"activeCount":77},[],{"trials":211,"activeCount":77},[],{"trials":213,"activeCount":77},[],{"trials":215,"activeCount":77},[],{"trials":217,"activeCount":73,"soonestReadout":42},[218],{"nctId":40,"briefTitle":41,"status":87,"phases":219,"primaryCompletion":42,"completion":196,"start":197,"enrollment":198,"conditions":220,"interventions":221},[70],[200],[43,202,203],{"intervention":203,"totalTrials":73,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":232,"NA":234},{"trials":225,"activeCount":77},[],{"trials":227,"activeCount":77},[],{"trials":229,"activeCount":77},[],{"trials":231,"activeCount":77},[],{"trials":233,"activeCount":77},[],{"trials":235,"activeCount":73,"soonestReadout":42},[236],{"nctId":40,"briefTitle":41,"status":87,"phases":237,"primaryCompletion":42,"completion":196,"start":197,"enrollment":198,"conditions":238,"interventions":239},[70],[200],[43,202,203],{"intervention":38,"totalTrials":73,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":252},{"trials":243,"activeCount":77},[],{"trials":245,"activeCount":77},[],{"trials":247,"activeCount":77},[],{"trials":249,"activeCount":77},[],{"trials":251,"activeCount":77},[],{"trials":253,"activeCount":73,"soonestReadout":37},[254],{"nctId":35,"briefTitle":36,"status":87,"phases":255,"primaryCompletion":37,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":260},[70],"2026-01-10","2022-02-10",140,[15],[38,261],"Liquid bubble sampling",{"intervention":261,"totalTrials":73,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":265,"activeCount":77},[],{"trials":267,"activeCount":77},[],{"trials":269,"activeCount":77},[],{"trials":271,"activeCount":77},[],{"trials":273,"activeCount":77},[],{"trials":275,"activeCount":73,"soonestReadout":37},[276],{"nctId":35,"briefTitle":36,"status":87,"phases":277,"primaryCompletion":37,"completion":256,"start":257,"enrollment":258,"conditions":278,"interventions":279},[70],[15],[38,261],{"intervention":63,"totalTrials":73,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":292},{"trials":283,"activeCount":77},[],{"trials":285,"activeCount":77},[],{"trials":287,"activeCount":77},[],{"trials":289,"activeCount":77},[],{"trials":291,"activeCount":77},[],{"trials":293,"activeCount":73,"soonestReadout":62},[294],{"nctId":60,"briefTitle":61,"status":87,"phases":295,"primaryCompletion":62,"completion":62,"start":296,"enrollment":297,"conditions":298,"interventions":300},[70],"2022-05-10",75,[299],"Chronic Lymphocytic Leukemia",[63],{"intervention":302,"totalTrials":73,"cells":303},"Curare",{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":327},{"trials":305,"activeCount":77},[],{"trials":307,"activeCount":77},[],{"trials":309,"activeCount":77},[],{"trials":311,"activeCount":77},[],{"trials":313,"activeCount":77},[314],{"nctId":315,"briefTitle":316,"status":317,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":325},"NCT02404142","Curarisation and Intubation Conditions During Videolaryngoscopy With Glidescope Titanium","COMPLETED",[69],"2016-04-05","2016-08-05","2015-02-20",64,[324],"Tracheal Intubation",[302,326],"saline isotonic solution",{"trials":328,"activeCount":77},[],{"intervention":326,"totalTrials":73,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":345},{"trials":332,"activeCount":77},[],{"trials":334,"activeCount":77},[],{"trials":336,"activeCount":77},[],{"trials":338,"activeCount":77},[],{"trials":340,"activeCount":77},[341],{"nctId":315,"briefTitle":316,"status":317,"phases":342,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":343,"interventions":344},[69],[324],[302,326],{"trials":346,"activeCount":77},[],{"intervention":348,"totalTrials":73,"cells":349},"propofol",{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":373},{"trials":351,"activeCount":77},[],{"trials":353,"activeCount":77},[],{"trials":355,"activeCount":77},[],{"trials":357,"activeCount":77},[],{"trials":359,"activeCount":77},[360],{"nctId":361,"briefTitle":362,"status":363,"phases":364,"primaryCompletion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT02816567","Laparoscopic Surgery and Abdominal Compliance","UNKNOWN",[69],"2018-01","2016-01",180,[369],"Patients Ongoing Elective Abdominal Laparoscopy",[348,371,372],"NMBA - cisatracurium","sufentanil",{"trials":374,"activeCount":77},[],{"intervention":371,"totalTrials":73,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":391},{"trials":378,"activeCount":77},[],{"trials":380,"activeCount":77},[],{"trials":382,"activeCount":77},[],{"trials":384,"activeCount":77},[],{"trials":386,"activeCount":77},[387],{"nctId":361,"briefTitle":362,"status":363,"phases":388,"primaryCompletion":365,"start":366,"enrollment":367,"conditions":389,"interventions":390},[69],[369],[348,371,372],{"trials":392,"activeCount":77},[],{"intervention":372,"totalTrials":73,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":409},{"trials":396,"activeCount":77},[],{"trials":398,"activeCount":77},[],{"trials":400,"activeCount":77},[],{"trials":402,"activeCount":77},[],{"trials":404,"activeCount":77},[405],{"nctId":361,"briefTitle":362,"status":363,"phases":406,"primaryCompletion":365,"start":366,"enrollment":367,"conditions":407,"interventions":408},[69],[369],[348,371,372],{"trials":410,"activeCount":77},[],{"intervention":412,"totalTrials":73,"cells":413},"Gardasil vaccine",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":436},{"trials":415,"activeCount":77},[],{"trials":417,"activeCount":77},[],{"trials":419,"activeCount":77},[],{"trials":421,"activeCount":77},[],{"trials":423,"activeCount":77},[424],{"nctId":425,"briefTitle":426,"status":317,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":434},"NCT02837926","Comparing Health Services Interventions for the Prevention of HPV-related Cancer",[69],"2017-12","2018-06","2016-05",63,[433],"Cervical Cancer",[412,435],"Cervarix®",{"trials":437,"activeCount":77},[],{"intervention":435,"totalTrials":73,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":454},{"trials":441,"activeCount":77},[],{"trials":443,"activeCount":77},[],{"trials":445,"activeCount":77},[],{"trials":447,"activeCount":77},[],{"trials":449,"activeCount":77},[450],{"nctId":425,"briefTitle":426,"status":317,"phases":451,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":452,"interventions":453},[69],[433],[412,435],{"trials":455,"activeCount":77},[],{"intervention":457,"totalTrials":73,"cells":458},"full dose at 16 UI\u002Fkg for Dysport or 6,5 UA\u002Fkg for Botox",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":477,"NA":479},{"trials":460,"activeCount":77},[],{"trials":462,"activeCount":77},[],{"trials":464,"activeCount":77},[],{"trials":466,"activeCount":77},[467],{"nctId":468,"briefTitle":469,"status":317,"phases":470,"primaryCompletion":430,"completion":430,"start":471,"enrollment":472,"conditions":473,"interventions":475},"NCT02816151","Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses",[68],"2011-02",29,[474],"Neurogenic Vesical Hyperactivity Syndrom",[457,476],"half dose at 8 UI\u002Fkg for Dysport or 3,25 UA\u002Fkg for Botox",{"trials":478,"activeCount":77},[],{"trials":480,"activeCount":77},[],{"intervention":476,"totalTrials":73,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":495,"NA":497},{"trials":484,"activeCount":77},[],{"trials":486,"activeCount":77},[],{"trials":488,"activeCount":77},[],{"trials":490,"activeCount":77},[491],{"nctId":468,"briefTitle":469,"status":317,"phases":492,"primaryCompletion":430,"completion":430,"start":471,"enrollment":472,"conditions":493,"interventions":494},[68],[474],[457,476],{"trials":496,"activeCount":77},[],{"trials":498,"activeCount":77},[],{"intervention":500,"totalTrials":73,"cells":501},"ceftazidime",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":520,"NA":522},{"trials":503,"activeCount":77},[],{"trials":505,"activeCount":77},[],{"trials":507,"activeCount":77},[],{"trials":509,"activeCount":77},[510],{"nctId":511,"briefTitle":512,"status":317,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT02837835","Lung Concentrations of Ceftazidime in Patients With Ventilator-associated Pneumonia",[68],"2008-02","2005-03",34,[518],"Pneumonia",[500,500],{"trials":521,"activeCount":77},[],{"trials":523,"activeCount":77},[],{"intervention":525,"totalTrials":73,"cells":526},"rituximab",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":546,"NA":548},{"trials":528,"activeCount":77},[],{"trials":530,"activeCount":77},[],{"trials":532,"activeCount":77},[],{"trials":534,"activeCount":77},[535],{"nctId":536,"briefTitle":537,"status":363,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":545},"NCT02867553","Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions",[68],"2018-07","2019-01","2011-10",36,[544],"Indolent Cutaneous B Cell Lymphomas",[525],{"trials":547,"activeCount":77},[],{"trials":549,"activeCount":77},[],{"intervention":551,"totalTrials":73,"cells":552},"2% adrenaline lidocaine associated with 4.2% sodium bicarbonate",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":573,"NA":575},{"trials":554,"activeCount":77},[],{"trials":556,"activeCount":77},[],{"trials":558,"activeCount":77},[],{"trials":560,"activeCount":77},[561],{"nctId":562,"briefTitle":563,"status":317,"phases":564,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT04255121","Bicarbonate Epidural Injection in Emergency Caesarian",[68],"2020-12-13","2021-02-26","2020-06-22",400,[570],"Emergency Caesarean",[551,572],"2% adrenaline lidocaine",{"trials":574,"activeCount":77},[],{"trials":576,"activeCount":77},[],{"intervention":572,"totalTrials":73,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":591,"NA":593},{"trials":580,"activeCount":77},[],{"trials":582,"activeCount":77},[],{"trials":584,"activeCount":77},[],{"trials":586,"activeCount":77},[587],{"nctId":562,"briefTitle":563,"status":317,"phases":588,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":589,"interventions":590},[68],[570],[551,572],{"trials":592,"activeCount":77},[],{"trials":594,"activeCount":77},[],{"intervention":596,"totalTrials":73,"cells":597},"experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":617,"NA":619},{"trials":599,"activeCount":77},[],{"trials":601,"activeCount":77},[],{"trials":603,"activeCount":77},[],{"trials":605,"activeCount":77},[606],{"nctId":607,"briefTitle":608,"status":317,"phases":609,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":615},"NCT02868944","Interest of the Injection of Morphine, in Addition to a Local Anesthetic When Performing a Combined Spinal-epidural for Labor Analgesia",[68],"2017-01-18","2014-08",144,[614],"Pregnant Women",[596,616],"control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.",{"trials":618,"activeCount":77},[],{"trials":620,"activeCount":77},[],{"intervention":616,"totalTrials":73,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":635,"NA":637},{"trials":624,"activeCount":77},[],{"trials":626,"activeCount":77},[],{"trials":628,"activeCount":77},[],{"trials":630,"activeCount":77},[631],{"nctId":607,"briefTitle":608,"status":317,"phases":632,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":633,"interventions":634},[68],[614],[596,616],{"trials":636,"activeCount":77},[],{"trials":638,"activeCount":77},[],{"intervention":640,"totalTrials":73,"cells":641},"Eplerenone",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":660,"PHASE4":662,"NA":664},{"trials":643,"activeCount":77},[],{"trials":645,"activeCount":77},[],{"trials":647,"activeCount":77},[648],{"nctId":649,"briefTitle":650,"status":363,"phases":651,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":659},"NCT01834768","EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety",[67],"2013-04","2013-12","2013-02",31,[657,658],"Chronic Kidney Insufficiency","Kidney Transplantation",[640],{"trials":661,"activeCount":77},[],{"trials":663,"activeCount":77},[],{"trials":665,"activeCount":77},[],{"intervention":667,"totalTrials":73,"cells":668},"Ustekinumab",{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":670,"activeCount":77},[],{"trials":672,"activeCount":77},[],{"trials":674,"activeCount":77},[675],{"nctId":676,"briefTitle":677,"status":317,"phases":678,"primaryCompletion":679,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":684},"NCT04117932","Efficacy and Safety of Ustekinumab in Bullous Pemphigoid",[67],"2022-12-22","2023-06-22","2020-03-11",18,[15],[667],{"trials":686,"activeCount":77},[],{"trials":688,"activeCount":77},[],{"trials":690,"activeCount":77},[],{"intervention":692,"totalTrials":73,"cells":693},"allogeneic umbilical cord-derived mesenchymal stem cells",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":695,"activeCount":77},[],{"trials":697,"activeCount":77},[],{"trials":699,"activeCount":77},[700],{"nctId":701,"briefTitle":702,"status":363,"phases":703,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":710},"NCT03994666","Cell Therapy in Critical Limb Ischemia",[67],"2020-12","2021-12","2019-09",30,[709],"Critical Limb Ischemia",[692],{"trials":712,"activeCount":77},[],{"trials":714,"activeCount":77},[],{"trials":716,"activeCount":77},[],{"intervention":718,"totalTrials":19,"cells":719},"blood sample withdrawn",{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":721,"activeCount":77},[],{"trials":723,"activeCount":77},[],{"trials":725,"activeCount":77},[],{"trials":727,"activeCount":77},[],{"trials":729,"activeCount":77},[],{"trials":731,"activeCount":77},[732,744,755,766],{"nctId":733,"briefTitle":734,"status":735,"phases":736,"primaryCompletion":737,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":743},"NCT02842528","Cognitive Vulnerability Factors in Alcohol-dependence","TERMINATED",[70],"2009-03","2009-07","2007-09",261,[742],"Alcoholism",[718],{"nctId":745,"briefTitle":746,"status":317,"phases":747,"primaryCompletion":748,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT02818465","Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients",[70],"2017-11-16","2015-03-30",100,[752],"Hemodialyzed Patients",[754],"Blood sample withdrawn",{"nctId":756,"briefTitle":757,"status":317,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":765},"NCT02826928","Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors",[70],"2020-02-28","2022-06-03","2016-10-26",116,[764],"Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)",[718],{"nctId":767,"briefTitle":768,"status":317,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":775},"NCT02857387","Markers of Vascular Aging and Coronary Syndrome",[70],"2018-08-27","2015-10",65,[774],"Acute Coronary Syndrome",[718],{"intervention":777,"totalTrials":778,"cells":779},"urine collection",2,{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":790},{"trials":781,"activeCount":77},[],{"trials":783,"activeCount":77},[],{"trials":785,"activeCount":77},[],{"trials":787,"activeCount":77},[],{"trials":789,"activeCount":77},[],{"trials":791,"activeCount":77},[792,802],{"nctId":793,"briefTitle":794,"status":317,"phases":795,"primaryCompletion":796,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":800},"NCT02807129","Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer",[70],"2023-01-16","2014-01-29",296,[27],[801,777],"blood withdrawn",{"nctId":803,"briefTitle":804,"status":317,"phases":805,"primaryCompletion":806,"completion":807,"start":430,"enrollment":808,"conditions":809,"interventions":811},"NCT02853292","Incidence, Risk Factors and Impact on Renal Function of the Appearance of Crystalluria Under High-dose Intravenous Amoxicillin",[],"2019-08","2022-05",153,[810],"Amoxicillin Crystalluria",[777],{"intervention":813,"totalTrials":778,"cells":814},"blood collection",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":816,"activeCount":77},[],{"trials":818,"activeCount":77},[],{"trials":820,"activeCount":77},[],{"trials":822,"activeCount":77},[],{"trials":824,"activeCount":77},[],{"trials":826,"activeCount":77},[827,837],{"nctId":828,"briefTitle":829,"status":363,"phases":830,"primaryCompletion":831,"start":832,"enrollment":833,"conditions":834,"interventions":836},"NCT02809300","Ankylosing Spondylitis and Antiphospholipid Antibodies",[70],"2017-03","2015-11",80,[835],"Ankylosing Spondylarthritis",[813],{"nctId":838,"briefTitle":839,"status":317,"phases":840,"primaryCompletion":841,"completion":841,"start":842,"enrollment":16,"conditions":843,"interventions":845},"NCT02808663","Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis",[70],"2017-02-01","2015-05-06",[844],"Severe Alcoholic Hepatitis",[846,813],"fecal calprotectin concentration",{"intervention":848,"totalTrials":778,"cells":849},"Blood sample",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":860},{"trials":851,"activeCount":77},[],{"trials":853,"activeCount":77},[],{"trials":855,"activeCount":77},[],{"trials":857,"activeCount":77},[],{"trials":859,"activeCount":77},[],{"trials":861,"activeCount":77},[862,872],{"nctId":863,"briefTitle":864,"status":317,"phases":865,"primaryCompletion":866,"completion":867,"start":868,"enrollment":833,"conditions":869,"interventions":871},"NCT04394572","Identification of New Diagnostic Protein Markers for Colorectal Cancer",[],"2021-07-29","2022-10-07","2021-01-07",[870],"Colorectal Cancer",[848],{"nctId":873,"briefTitle":874,"status":317,"phases":875,"primaryCompletion":876,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":882},"NCT04220034","Autoantibodies Prevalence During Checkpoint Inhibitor Treatment",[],"2024-07-22","2025-11-28","2020-01-15",183,[881],"Autoimmune Adverse Effects of Anti-neoplasic Drug",[848],{"intervention":884,"totalTrials":778,"cells":885},"genetic analysis",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":892,"PHASE4":894,"NA":896},{"trials":887,"activeCount":77},[],{"trials":889,"activeCount":77},[],{"trials":891,"activeCount":77},[],{"trials":893,"activeCount":77},[],{"trials":895,"activeCount":77},[],{"trials":897,"activeCount":77},[898,909],{"nctId":899,"briefTitle":900,"status":317,"phases":901,"primaryCompletion":902,"completion":903,"start":904,"enrollment":905,"conditions":906,"interventions":908},"NCT02879422","Genetic Markers and Proliferative Diabetic Retinopathy",[70],"2020-03-03","2021-01","2013-10-16",302,[907],"Proliferative Diabetic Retinopathy",[884],{"nctId":910,"briefTitle":911,"status":363,"phases":912,"primaryCompletion":913,"completion":914,"start":915,"enrollment":258,"conditions":916,"interventions":918},"NCT03338985","Role of Senescence in the Development of Endometrial Cancer",[70],"2019-10-16","2020-04-16","2017-10-16",[917],"Endometrial Hyperplasia and Endometrial Cancers",[919],"Genetic analysis",{"intervention":921,"totalTrials":73,"cells":922},"whole blood collection",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":924,"activeCount":77},[],{"trials":926,"activeCount":77},[],{"trials":928,"activeCount":77},[],{"trials":930,"activeCount":77},[],{"trials":932,"activeCount":77},[],{"trials":934,"activeCount":77},[935],{"nctId":936,"briefTitle":937,"status":317,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":750,"conditions":941,"interventions":943},"NCT02792283","Platelet Function in Hemodialysis Patient",[70],"2017-12-29","2016-01-28",[942],"Chronic Kidney Disease",[921],{"intervention":801,"totalTrials":73,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":947,"activeCount":77},[],{"trials":949,"activeCount":77},[],{"trials":951,"activeCount":77},[],{"trials":953,"activeCount":77},[],{"trials":955,"activeCount":77},[],{"trials":957,"activeCount":77},[958],{"nctId":793,"briefTitle":794,"status":317,"phases":959,"primaryCompletion":796,"completion":796,"start":797,"enrollment":798,"conditions":960,"interventions":961},[70],[27],[801,777],{"intervention":963,"totalTrials":73,"cells":964},"pyrosequencing",{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":966,"activeCount":77},[],{"trials":968,"activeCount":77},[],{"trials":970,"activeCount":77},[],{"trials":972,"activeCount":77},[],{"trials":974,"activeCount":77},[],{"trials":976,"activeCount":77},[977],{"nctId":978,"briefTitle":979,"status":317,"phases":980,"primaryCompletion":981,"completion":831,"start":430,"enrollment":982,"conditions":983,"interventions":985},"NCT02786602","LRP1 Methylation and Colon Cancer",[],"2016-11",345,[984],"Colon Cancer",[963],{"intervention":987,"totalTrials":73,"cells":988},"spinal fluid collection",{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":990,"activeCount":77},[],{"trials":992,"activeCount":77},[],{"trials":994,"activeCount":77},[],{"trials":996,"activeCount":77},[],{"trials":998,"activeCount":77},[],{"trials":1000,"activeCount":77},[1001],{"nctId":1002,"briefTitle":1003,"status":317,"phases":1004,"primaryCompletion":1005,"completion":1005,"start":1006,"enrollment":1007,"conditions":1008,"interventions":1009},"NCT02770482","Amyloid Beta-peptide 1-40 and Alzheimer's Disease",[70],"2018-03-14","2014-06",204,[23],[987],{"intervention":1011,"totalTrials":73,"cells":1012},"Somatic Genetic",{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1014,"activeCount":77},[],{"trials":1016,"activeCount":77},[],{"trials":1018,"activeCount":77},[],{"trials":1020,"activeCount":77},[],{"trials":1022,"activeCount":77},[],{"trials":1024,"activeCount":77},[1025],{"nctId":1026,"briefTitle":1027,"status":317,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":772,"conditions":1032,"interventions":1034},"NCT03319693","Molecular Characterization of Primary Mucosal Melanoma",[],"2019-04-28","2021-04-28","2017-08-28",[1033],"Mucosal Melanoma",[1011],{"intervention":1036,"totalTrials":73,"cells":1037},"Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level",{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1039,"activeCount":77},[],{"trials":1041,"activeCount":77},[],{"trials":1043,"activeCount":77},[],{"trials":1045,"activeCount":77},[],{"trials":1047,"activeCount":77},[],{"trials":1049,"activeCount":77},[1050],{"nctId":1051,"briefTitle":1052,"status":317,"phases":1053,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":134,"conditions":1057,"interventions":1059},"NCT03852888","Kinetics of Elimination of Methotrexate and Its Major Metabolite 7-OH-methotrexate for Observant Patients",[70],"2020-11-23","2021-11-25","2018-11-14",[1058],"Rheumatoid Arthritis",[1036],{"intervention":1061,"totalTrials":73,"cells":1062},"bile sample analysis",{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1069,"PHASE4":1071,"NA":1073},{"trials":1064,"activeCount":77},[],{"trials":1066,"activeCount":77},[],{"trials":1068,"activeCount":77},[],{"trials":1070,"activeCount":77},[],{"trials":1072,"activeCount":77},[],{"trials":1074,"activeCount":77},[1075],{"nctId":1076,"briefTitle":1077,"status":317,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":750,"conditions":1081,"interventions":1083},"NCT02893085","Pancreatico-biliary Tumor Mutation Profiling in Bile Samples",[],"2016-10","2015-09",[1082],"Cholangiocarcinoma, Cancer of the Head of the Pancreas",[1061,1084],"biochemical markers, VEGF and MMPs, in bile samples",{"intervention":1084,"totalTrials":73,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1088,"activeCount":77},[],{"trials":1090,"activeCount":77},[],{"trials":1092,"activeCount":77},[],{"trials":1094,"activeCount":77},[],{"trials":1096,"activeCount":77},[],{"trials":1098,"activeCount":77},[1099],{"nctId":1076,"briefTitle":1077,"status":317,"phases":1100,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":750,"conditions":1101,"interventions":1102},[],[1082],[1061,1084],{"intervention":1104,"totalTrials":73,"cells":1105},"modified Peritoneal Equilibration test",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1107,"activeCount":77},[],{"trials":1109,"activeCount":77},[],{"trials":1111,"activeCount":77},[],{"trials":1113,"activeCount":77},[],{"trials":1115,"activeCount":77},[],{"trials":1117,"activeCount":77},[1118],{"nctId":1119,"briefTitle":1120,"status":363,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1130},"NCT03322410","Hydratation Status at Initiation of Peritoneal Dialysis: Study of the Role of Peritoneal Permeability",[70],"2019-11-01","2020-11-01","2017-11-01",40,[1127,1128,1129,942],"Fluid Overload","Peritoneal Hyperpermeability","Peritoneal Dialysis",[1104],{"intervention":1132,"totalTrials":73,"cells":1133},"treatment with topical superpotent corticosteroid therapy",{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1135,"activeCount":77},[],{"trials":1137,"activeCount":77},[],{"trials":1139,"activeCount":77},[],{"trials":1141,"activeCount":77},[],{"trials":1143,"activeCount":77},[],{"trials":1145,"activeCount":77},[1146],{"nctId":1147,"briefTitle":1148,"status":317,"phases":1149,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":1153,"conditions":1154,"interventions":1155},"NCT02837965","Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid",[],"2018-07-12","2018-12-31","2013-09-26",149,[15],[1132,1156,1157,1156,1156],"treatment with systemic therapy","treatment systemic therapy",{"intervention":1156,"totalTrials":73,"cells":1159},{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1164,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1161,"activeCount":77},[],{"trials":1163,"activeCount":77},[],{"trials":1165,"activeCount":77},[],{"trials":1167,"activeCount":77},[],{"trials":1169,"activeCount":77},[],{"trials":1171,"activeCount":77},[1172],{"nctId":1147,"briefTitle":1148,"status":317,"phases":1173,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":1153,"conditions":1174,"interventions":1175},[],[15],[1132,1156,1157,1156,1156],{"intervention":1157,"totalTrials":73,"cells":1177},{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1179,"activeCount":77},[],{"trials":1181,"activeCount":77},[],{"trials":1183,"activeCount":77},[],{"trials":1185,"activeCount":77},[],{"trials":1187,"activeCount":77},[],{"trials":1189,"activeCount":77},[1190],{"nctId":1147,"briefTitle":1148,"status":317,"phases":1191,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":1153,"conditions":1192,"interventions":1193},[],[15],[1132,1156,1157,1156,1156],{"intervention":1195,"totalTrials":73,"cells":1196},"serology",{"EARLY_PHASE1":1197,"PHASE1":1199,"PHASE2":1201,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1198,"activeCount":77},[],{"trials":1200,"activeCount":77},[],{"trials":1202,"activeCount":77},[],{"trials":1204,"activeCount":77},[],{"trials":1206,"activeCount":77},[],{"trials":1208,"activeCount":77},[1209],{"nctId":1210,"briefTitle":1211,"status":317,"phases":1212,"primaryCompletion":1213,"completion":1214,"start":1215,"enrollment":1216,"conditions":1217,"interventions":1219},"NCT04553575","CoViD-19 Patient in Reims University Hospital in March to April 2020",[],"2022-05-24","2022-08-04","2020-09-25",127,[1218],"Coronavirus Infections",[1195],{"intervention":846,"totalTrials":73,"cells":1221},{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1223,"activeCount":77},[],{"trials":1225,"activeCount":77},[],{"trials":1227,"activeCount":77},[],{"trials":1229,"activeCount":77},[],{"trials":1231,"activeCount":77},[],{"trials":1233,"activeCount":77},[1234],{"nctId":838,"briefTitle":839,"status":317,"phases":1235,"primaryCompletion":841,"completion":841,"start":842,"enrollment":16,"conditions":1236,"interventions":1237},[70],[844],[846,813],{"intervention":1239,"totalTrials":73,"cells":1240},"Additional taking blood",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1242,"activeCount":77},[],{"trials":1244,"activeCount":77},[],{"trials":1246,"activeCount":77},[],{"trials":1248,"activeCount":77},[],{"trials":1250,"activeCount":77},[],{"trials":1252,"activeCount":77},[1253],{"nctId":1254,"briefTitle":1255,"status":317,"phases":1256,"primaryCompletion":1257,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1263},"NCT02787980","Dosage of Serum Tryptase Levels in a Population of Premature Newborns to Evaluate Mast Cell Activity",[70],"2018-06-05","2019-12-31","2015-10-12",87,[1262],"Premature Newborns",[1239],{"intervention":1265,"totalTrials":73,"cells":1266},"chemotherapy",{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1268,"activeCount":77},[],{"trials":1270,"activeCount":77},[],{"trials":1272,"activeCount":77},[],{"trials":1274,"activeCount":77},[],{"trials":1276,"activeCount":77},[],{"trials":1278,"activeCount":77},[1279],{"nctId":1280,"briefTitle":1281,"status":317,"phases":1282,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1292},"NCT02797197","Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy",[70],"2017-02-15","2016-05-18",201,[1287,1288,1289,1290,1291],"Handgrip Strength Test","Sarcopenia","Digestive Cancer","Muscle Strength","Chemotherapy",[1265],{"intervention":1294,"totalTrials":73,"cells":1295},"blood sample collection",{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1297,"activeCount":77},[],{"trials":1299,"activeCount":77},[],{"trials":1301,"activeCount":77},[],{"trials":1303,"activeCount":77},[],{"trials":1305,"activeCount":77},[],{"trials":1307,"activeCount":77},[1308],{"nctId":1309,"briefTitle":1310,"status":363,"phases":1311,"primaryCompletion":1312,"start":471,"enrollment":1313,"conditions":1314,"interventions":1316},"NCT02793427","Patient With Any Pathology (According to the Appreciation of the Investigator) Which Could Disturb the Participation in the Study",[70],"2019-06",160,[1315],"Type 1 Diabetes in Children",[1294],{"intervention":1318,"totalTrials":73,"cells":1319},"blood collection for mutation characterization",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1326,"PHASE4":1328,"NA":1330},{"trials":1321,"activeCount":77},[],{"trials":1323,"activeCount":77},[],{"trials":1325,"activeCount":77},[],{"trials":1327,"activeCount":77},[],{"trials":1329,"activeCount":77},[],{"trials":1331,"activeCount":77},[1332],{"nctId":1333,"briefTitle":1334,"status":317,"phases":1335,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":1339,"conditions":1340,"interventions":1342},"NCT02810496","Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia",[70],"2016-10-02","2016-12-31","2012-04-02",150,[1341],"General Glucocorticoid Resistance",[1318],{"intervention":1344,"totalTrials":73,"cells":1345},"cyclopentolate 0.5% eye drops",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1356},{"trials":1347,"activeCount":77},[],{"trials":1349,"activeCount":77},[],{"trials":1351,"activeCount":77},[],{"trials":1353,"activeCount":77},[],{"trials":1355,"activeCount":77},[],{"trials":1357,"activeCount":77},[1358],{"nctId":1359,"briefTitle":1360,"status":317,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1367},"NCT03375996","Evaluation of a Protocol of Pupil Dilation Before Laser-assisted Cataract Surgery",[],"2024-08-21","2018-06-01",60,[1366],"Cataract Surgery",[1344],{"intervention":1369,"totalTrials":73,"cells":1370},"surgery",{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1372,"activeCount":77},[],{"trials":1374,"activeCount":77},[],{"trials":1376,"activeCount":77},[],{"trials":1378,"activeCount":77},[],{"trials":1380,"activeCount":77},[],{"trials":1382,"activeCount":77},[1383],{"nctId":1384,"briefTitle":1385,"status":317,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":1389,"conditions":1390,"interventions":1392},"NCT02833896","Endometrial Cancer and Array CGH",[],"2016-03","2010-11",95,[1391],"Cancer of the Endometrium",[1369],{"intervention":1394,"totalTrials":73,"cells":1395},"Decrease per-dialytic heparin therapy",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1404,"NA":1406},{"trials":1397,"activeCount":77},[],{"trials":1399,"activeCount":77},[],{"trials":1401,"activeCount":77},[],{"trials":1403,"activeCount":77},[],{"trials":1405,"activeCount":77},[],{"trials":1407,"activeCount":77},[1408],{"nctId":1409,"briefTitle":1410,"status":363,"phases":1411,"primaryCompletion":903,"completion":1412,"start":1413,"enrollment":1414,"conditions":1415,"interventions":1426},"NCT04462614","Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA",[70],"2021-07","2020-08",49,[1416,1417,1418,1419,1420,1421,1422,1423,1424,1425],"Chronic Hemolysis","VKA","Anticoagulants \u002F Administration & Dosage","Coated Materials","Biocompatible","Heparin \u002F Administration & Dosage","Membranes Artificial","Prospective Studies","Renal Dialysis \u002F Methods","Renal Insufficiency \u002F Therapy",[1394],{"intervention":1428,"totalTrials":73,"cells":1429},"Research of constitutional genetic alterations",{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1431,"activeCount":77},[],{"trials":1433,"activeCount":77},[],{"trials":1435,"activeCount":77},[],{"trials":1437,"activeCount":77},[],{"trials":1439,"activeCount":77},[],{"trials":1441,"activeCount":77},[1442],{"nctId":1443,"briefTitle":1444,"status":363,"phases":1445,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1364,"conditions":1449,"interventions":1451},"NCT03622333","Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)",[70],"2022-05-28","2022-11-28","2018-05-28",[1450],"Small Intestinal Carcinoid Tumors",[1428],{"intervention":1453,"totalTrials":73,"cells":1454},"Nusinersen",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1456,"activeCount":77},[],{"trials":1458,"activeCount":77},[],{"trials":1460,"activeCount":77},[],{"trials":1462,"activeCount":77},[],{"trials":1464,"activeCount":77},[],{"trials":1466,"activeCount":77},[1467],{"nctId":1468,"briefTitle":1469,"status":317,"phases":1470,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":19,"conditions":1474,"interventions":1476},"NCT04576494","Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)",[70],"2023-01-24","2023-09-08","2022-01-24",[1475],"Spinal Muscular Atrophy",[1453],{"intervention":1478,"totalTrials":73,"cells":1479},"Human papillomavirus genotyping",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1481,"activeCount":77},[],{"trials":1483,"activeCount":77},[],{"trials":1485,"activeCount":77},[],{"trials":1487,"activeCount":77},[],{"trials":1489,"activeCount":77},[],{"trials":1491,"activeCount":77},[1492],{"nctId":1493,"briefTitle":1494,"status":317,"phases":1495,"primaryCompletion":1496,"start":1497,"enrollment":1498,"conditions":1499,"interventions":1501},"NCT02809352","Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program for Cervical Cancer",[],"2014-12","2012-07",348,[1500],"HPV Infection",[1478],{"intervention":1503,"totalTrials":73,"cells":1504},"Prednisolone",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1513,"NA":1515},{"trials":1506,"activeCount":77},[],{"trials":1508,"activeCount":77},[],{"trials":1510,"activeCount":77},[],{"trials":1512,"activeCount":77},[],{"trials":1514,"activeCount":77},[],{"trials":1516,"activeCount":77},[1517],{"nctId":1518,"briefTitle":1519,"status":317,"phases":1520,"primaryCompletion":1521,"completion":1521,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1527},"NCT05105256","Platelet-rich Plasma Infiltration Versus Corticosteroid Infiltration (Prednisolone) in Treatment of Lumbar Facet Joint Syndrome",[70],"2024-05-16","2021-12-21",76,[1525,1526],"Low Back Pain","Osteoarthritis",[1503,1528],"Platelet-rich plasma",{"intervention":1528,"totalTrials":73,"cells":1530},{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1532,"activeCount":77},[],{"trials":1534,"activeCount":77},[],{"trials":1536,"activeCount":77},[],{"trials":1538,"activeCount":77},[],{"trials":1540,"activeCount":77},[],{"trials":1542,"activeCount":77},[1543],{"nctId":1518,"briefTitle":1519,"status":317,"phases":1544,"primaryCompletion":1521,"completion":1521,"start":1522,"enrollment":1523,"conditions":1545,"interventions":1546},[70],[1525,1526],[1503,1528],{"intervention":1548,"totalTrials":73,"cells":1549},"Nitrous oxide",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1551,"activeCount":77},[],{"trials":1553,"activeCount":77},[],{"trials":1555,"activeCount":77},[],{"trials":1557,"activeCount":77},[],{"trials":1559,"activeCount":77},[],{"trials":1561,"activeCount":77},[1562],{"nctId":1563,"briefTitle":1564,"status":363,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1572},"NCT05388942","Virtual Reality Hypnosis Versus Inhaled Nitrous Oxide in Anterior Shoulder Dislocation Reduction: an Open Multicenter Randomized Controlled Trial",[70],"2023-10-09","2024-01-09","2022-10-09",126,[1571],"Shoulder Dislocation",[1548],{"intervention":1574,"totalTrials":73,"cells":1575},"biological fluids (serum, bronchoalveolar lavage and pulmonary aspiration) and bronchial biopsies collection",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1577,"activeCount":77},[],{"trials":1579,"activeCount":77},[],{"trials":1581,"activeCount":77},[],{"trials":1583,"activeCount":77},[],{"trials":1585,"activeCount":77},[],{"trials":1587,"activeCount":77},[1588],{"nctId":1589,"briefTitle":1590,"status":317,"phases":1591,"primaryCompletion":428,"completion":428,"start":1592,"enrollment":1593,"conditions":1594,"interventions":1599},"NCT02788643","Study of Collagen IV and XIX in Bronchoalveolar Lavage, Pulmonary Aspiration and Bronchial Biopsies",[],"2014-05",51,[1595,1596,1597,1598],"Chronic Obstructive Bronchopneumopathy","Infectious Pneumonia","Pneumonitis","Lung Cancer",[1574],{"intervention":1601,"totalTrials":73,"cells":1602},"Immunohistochemistry and clinical analyses on patients and corneas",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1609,"PHASE4":1611,"NA":1613},{"trials":1604,"activeCount":77},[],{"trials":1606,"activeCount":77},[],{"trials":1608,"activeCount":77},[],{"trials":1610,"activeCount":77},[],{"trials":1612,"activeCount":77},[],{"trials":1614,"activeCount":77},[1615],{"nctId":1616,"briefTitle":1617,"status":317,"phases":1618,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1627},"NCT05009407","CD160 Expression in Corneal Vessels",[],"2025-12-22","2021-04-21",43,[1623,1624,1625,1626],"Corneal Graft Rejection","CD160","Angiogenesis","Lymphangiogenesis",[1601]]